Cargando…

Multidrug-Resistant Tuberculosis Treatment Outcome and Associated Factors at the University of Gondar Comprehensive Specialized Hospital: A Ten-Year Retrospective Study

BACKGROUND: Multidrug-resistant tuberculosis (MDR-TB) remains a public health crisis and a health security threat worldwide. Poor public health infrastructure, inefficient infection control and mismanagement of TB treatment are among the reasons for the continuous emergence and spread of drug-resist...

Descripción completa

Detalles Bibliográficos
Autores principales: Belachew, Teshome, Yaheya, Seid, Tilahun, Nehemia, Gebrie, Eshet, Seid, Rim, Nega, Tilahun, Biset, Sirak
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9172731/
https://www.ncbi.nlm.nih.gov/pubmed/35686191
http://dx.doi.org/10.2147/IDR.S365394
_version_ 1784721917245128704
author Belachew, Teshome
Yaheya, Seid
Tilahun, Nehemia
Gebrie, Eshet
Seid, Rim
Nega, Tilahun
Biset, Sirak
author_facet Belachew, Teshome
Yaheya, Seid
Tilahun, Nehemia
Gebrie, Eshet
Seid, Rim
Nega, Tilahun
Biset, Sirak
author_sort Belachew, Teshome
collection PubMed
description BACKGROUND: Multidrug-resistant tuberculosis (MDR-TB) remains a public health crisis and a health security threat worldwide. Poor public health infrastructure, inefficient infection control and mismanagement of TB treatment are among the reasons for the continuous emergence and spread of drug-resistant TB (DR-TB). The final treatment outcome is the most direct measurement of TB control programs. Therefore, this study sought to determine the proportions and predictors of TB treatment outcomes among MDR/RR-TB treated patients. METHODS: A 10-year, 2011 to 2021, hospital-based retrospective cohort study was conducted at the University of Gondar Comprehensive Specialized Hospital. The records of 408 MDR-TB patients, 389 with treatment outcome and 19 on treatment, were collected using a structured checklist. RESULTS: A total of 389 patients with a recorded MDR/RR-TB treatment outcome were included. The treatment success rate was 77.12%, with 58.35% cured and 18.76% treatment completed. The proportion of death rate, treatment default loss to follow-up, treatment failure, and unknown treatment outcome was 9.25%, 6.94%, 3.1%, and 3.6%, respectively. Regarding the patient category, the most successful treatment outcome (83.5%) came from patients diagnosed with relapse cases, followed by new cases (81.8%). An unsuccessful treatment outcome was significantly associated with patients aged >44 years (AOR, 3.3, 95% CI = 1.55–6.99). CONCLUSION AND RECOMMENDATIONS: This study indicated that nearly 23% of MDR/RR-TB patients had unsuccessful treatment outcomes and being older was significantly correlated with these outcomes. For better outcomes, it is recommended to strengthen combined treatment adherence interventions and evaluate treatment regimens and administration options. A prospective cohort study may be required to investigate the full range of potential causes of unfavorable outcomes.
format Online
Article
Text
id pubmed-9172731
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-91727312022-06-08 Multidrug-Resistant Tuberculosis Treatment Outcome and Associated Factors at the University of Gondar Comprehensive Specialized Hospital: A Ten-Year Retrospective Study Belachew, Teshome Yaheya, Seid Tilahun, Nehemia Gebrie, Eshet Seid, Rim Nega, Tilahun Biset, Sirak Infect Drug Resist Original Research BACKGROUND: Multidrug-resistant tuberculosis (MDR-TB) remains a public health crisis and a health security threat worldwide. Poor public health infrastructure, inefficient infection control and mismanagement of TB treatment are among the reasons for the continuous emergence and spread of drug-resistant TB (DR-TB). The final treatment outcome is the most direct measurement of TB control programs. Therefore, this study sought to determine the proportions and predictors of TB treatment outcomes among MDR/RR-TB treated patients. METHODS: A 10-year, 2011 to 2021, hospital-based retrospective cohort study was conducted at the University of Gondar Comprehensive Specialized Hospital. The records of 408 MDR-TB patients, 389 with treatment outcome and 19 on treatment, were collected using a structured checklist. RESULTS: A total of 389 patients with a recorded MDR/RR-TB treatment outcome were included. The treatment success rate was 77.12%, with 58.35% cured and 18.76% treatment completed. The proportion of death rate, treatment default loss to follow-up, treatment failure, and unknown treatment outcome was 9.25%, 6.94%, 3.1%, and 3.6%, respectively. Regarding the patient category, the most successful treatment outcome (83.5%) came from patients diagnosed with relapse cases, followed by new cases (81.8%). An unsuccessful treatment outcome was significantly associated with patients aged >44 years (AOR, 3.3, 95% CI = 1.55–6.99). CONCLUSION AND RECOMMENDATIONS: This study indicated that nearly 23% of MDR/RR-TB patients had unsuccessful treatment outcomes and being older was significantly correlated with these outcomes. For better outcomes, it is recommended to strengthen combined treatment adherence interventions and evaluate treatment regimens and administration options. A prospective cohort study may be required to investigate the full range of potential causes of unfavorable outcomes. Dove 2022-06-03 /pmc/articles/PMC9172731/ /pubmed/35686191 http://dx.doi.org/10.2147/IDR.S365394 Text en © 2022 Belachew et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Belachew, Teshome
Yaheya, Seid
Tilahun, Nehemia
Gebrie, Eshet
Seid, Rim
Nega, Tilahun
Biset, Sirak
Multidrug-Resistant Tuberculosis Treatment Outcome and Associated Factors at the University of Gondar Comprehensive Specialized Hospital: A Ten-Year Retrospective Study
title Multidrug-Resistant Tuberculosis Treatment Outcome and Associated Factors at the University of Gondar Comprehensive Specialized Hospital: A Ten-Year Retrospective Study
title_full Multidrug-Resistant Tuberculosis Treatment Outcome and Associated Factors at the University of Gondar Comprehensive Specialized Hospital: A Ten-Year Retrospective Study
title_fullStr Multidrug-Resistant Tuberculosis Treatment Outcome and Associated Factors at the University of Gondar Comprehensive Specialized Hospital: A Ten-Year Retrospective Study
title_full_unstemmed Multidrug-Resistant Tuberculosis Treatment Outcome and Associated Factors at the University of Gondar Comprehensive Specialized Hospital: A Ten-Year Retrospective Study
title_short Multidrug-Resistant Tuberculosis Treatment Outcome and Associated Factors at the University of Gondar Comprehensive Specialized Hospital: A Ten-Year Retrospective Study
title_sort multidrug-resistant tuberculosis treatment outcome and associated factors at the university of gondar comprehensive specialized hospital: a ten-year retrospective study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9172731/
https://www.ncbi.nlm.nih.gov/pubmed/35686191
http://dx.doi.org/10.2147/IDR.S365394
work_keys_str_mv AT belachewteshome multidrugresistanttuberculosistreatmentoutcomeandassociatedfactorsattheuniversityofgondarcomprehensivespecializedhospitalatenyearretrospectivestudy
AT yaheyaseid multidrugresistanttuberculosistreatmentoutcomeandassociatedfactorsattheuniversityofgondarcomprehensivespecializedhospitalatenyearretrospectivestudy
AT tilahunnehemia multidrugresistanttuberculosistreatmentoutcomeandassociatedfactorsattheuniversityofgondarcomprehensivespecializedhospitalatenyearretrospectivestudy
AT gebrieeshet multidrugresistanttuberculosistreatmentoutcomeandassociatedfactorsattheuniversityofgondarcomprehensivespecializedhospitalatenyearretrospectivestudy
AT seidrim multidrugresistanttuberculosistreatmentoutcomeandassociatedfactorsattheuniversityofgondarcomprehensivespecializedhospitalatenyearretrospectivestudy
AT negatilahun multidrugresistanttuberculosistreatmentoutcomeandassociatedfactorsattheuniversityofgondarcomprehensivespecializedhospitalatenyearretrospectivestudy
AT bisetsirak multidrugresistanttuberculosistreatmentoutcomeandassociatedfactorsattheuniversityofgondarcomprehensivespecializedhospitalatenyearretrospectivestudy